Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Ko J, Mayo T, Bergfeld W, Dutronc Y, Yu G, Ball S, Somani N, Craiglow B. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology 2023, 159: 970-976. PMID: 37556146, PMCID: PMC10413213, DOI: 10.1001/jamadermatol.2023.2581.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSALT scoreAlopecia areataWeek 76Response rateWeek 52Week 36Pooled analysisHair lossLong-term extension dataEyebrow hair lossProportion of patientsWeeks of therapyClinician-reported outcomesHigh response rateHair loss scoreSelective JanusAdult patientsClinical outcomesOutcome scoresHair regrowthClinical trialsMAIN OUTCOMETreatment doseBaricitinibJanus kinase inhibitors for alopecia areata
King B, Craiglow B. Janus kinase inhibitors for alopecia areata. Journal Of The American Academy Of Dermatology 2023, 89: s29-s32. PMID: 37591562, DOI: 10.1016/j.jaad.2023.05.049.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataClinical Trials, Phase III as TopicHumansJanus Kinase InhibitorsPatient SelectionScalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. Journal Of Dermatological Treatment 2023, 34: 2227299. PMID: 37381691, DOI: 10.1080/09546634.2023.2227299.Peer-Reviewed Original ResearchConceptsSevere alopecia areataHealth-related qualityHair regrowthAlopecia areataMinimal regrowthBaseline Hospital AnxietyProportion of patientsPhase 3 trialDepression Scale scoresGreater improvementBaricitinib 2Daily placeboMore patientsWeek 36Hospital AnxietyTreatment allocationSkindex-16PatientsScale scoreScore changePsychological symptomsPsychological burdenAreataTrials